RxDoctor Payments DataLook up a doctor →

Vikas Sayal, MD

Pulmonary Disease · Bullhead City, AZNPI 1811109226

Payments from drug & device makers

$3,674,561in general payments, 2019–2025

Across 1,421 payments — averaging $2585.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1.1M
  • GSK$705K
  • Sanofi US Services Inc.$413K
  • Takeda Pharmaceuticals U.S.A., Inc.$408K
  • AstraZeneca$339K
  • Chiesi USA, Inc.$253K
  • plus $488K from 46 others
$187in research payments, 2019–2025

Across 1 payment — averaging $187.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$187

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,674,561 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$945,179
Medicare patients
1,530
Services billed
14,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Bullhead City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →